Vmn1r-ps4 activators constitute a diverse group of chemical compounds that indirectly promote the functional activity of Vmn1r-ps4 by primarily modulating cyclic nucleotide levels within cells. Isobutylmethylxanthine and Caffeine, as phosphodiesterase inhibitors, enhance Vmn1r-ps4 activity by increasing intracellular cAMP levels, a crucial component of the signaling pathways that Vmn1r-ps4 is involved in. Similarly, Forskolin, by directly stimulating adenylate cyclase, and Sildenafil and Zaprinast, by inhibiting PDE5, raise cAMP and cGMP levels, creating an environment conducive to Vmn1r-ps4 signaling. Rolipram, through its selective inhibition of phosphodiesterase 4, further amplifies cAMP levels, potentiating the pathways in which Vmn1r-ps4 operates. These compounds, by elevating cAMP or cGMP, indirectly influence Vmn1r-ps4's functional activities related to cellular signaling.
The second set of activators includes Capsaicin, which activates TRPV1 channels leading to downstream cAMP modulation, and Resveratrol, which engages sirtuin pathways that subsequently impact Vmn1r-ps4 signaling cascades. Yohimbine contributes to this modulation by blocking alpha-2 adrenergic receptors, thereby potentially increasing cAMP levels and indirectly enhancing Vmn1r-ps4 signaling. The involvement of Ginsenoside Rg1, Theophylline, and Vinpocetine further underscores the importance of cAMP and cGMP in Vmn1r-ps4 activation. These compounds, through their unique interactions with cellular signaling molecules and pathways, collectively create a biochemical environment that favors the enhanced activity of Vmn1r-ps4, highlighting the intricate network of cellular interactions that govern its functional dynamics.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Enhances Vmn1r-ps4 activity by inhibiting phosphodiesterases, thereby increasing cAMP levels which are crucial for the signaling pathways Vmn1r-ps4 is involved in. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Selectively inhibits phosphodiesterase 4, raising cAMP levels, thereby potentiating the Vmn1r-ps4 mediated signaling pathways. | ||||||
Capsaicin | 404-86-4 | sc-3577 sc-3577C sc-3577D sc-3577A | 50 mg 250 mg 500 mg 1 g | $96.00 $160.00 $240.00 $405.00 | 26 | |
Activates TRPV1 channels, which can lead to downstream effects on cAMP levels, indirectly influencing Vmn1r-ps4 activity. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Stimulates sirtuin pathways that indirectly affect the signaling cascades involving Vmn1r-ps4. | ||||||
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 50 g 100 g 250 g 1 kg 5 kg | $33.00 $67.00 $97.00 $192.00 $775.00 | 13 | |
As a phosphodiesterase inhibitor, it raises intracellular cAMP levels, indirectly facilitating Vmn1r-ps4 signaling. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Inhibits phosphodiesterases, particularly PDE5, leading to elevated cAMP and cGMP levels, indirectly enhancing Vmn1r-ps4 activity. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
Blocks alpha-2 adrenergic receptors, which can lead to increased cAMP levels, indirectly augmenting Vmn1r-ps4 signaling. | ||||||
Ginsenoside Rg1 | 22427-39-0 | sc-205708 sc-205708A | 5 mg 10 mg | $265.00 $486.00 | ||
Influences cAMP pathways, indirectly modulating Vmn1r-ps4 activity. | ||||||
Theophylline | 58-55-9 | sc-202835 sc-202835A sc-202835B | 5 g 25 g 100 g | $20.00 $32.00 $85.00 | 6 | |
Inhibits phosphodiesterases, increasing cAMP levels and indirectly supporting Vmn1r-ps4 mediated pathways. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Inhibits PDE1, leading to increased cAMP and cGMP levels, indirectly enhancing the signaling pathways involving Vmn1r-ps4. | ||||||